Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Amazon Explores AI Content Marketplace With Media Publishers 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CANTON, Mass., April 04, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
